Bortezomib-Promomed

The main articles are:

• Cancer (cancer)
• Cancer treatment
• Drugs to treat cancer
• Leukemia (leukemia, blood cancer)

2023: Obtaining a Marketing Authorization

Bortezomib-Promomed used for multiple myeloma received marketing authorization. It is also prescribed to patients with mantle cell lymphoma, who have disease progression after several courses of treatment. Promomed announced this on March 9, 2023.

Bortezomib is a modified boric acid and is a proteasome inhibitor. The mechanism of action of the drug is to accelerate the cleavage of proteins and regulate their intracellular concentrations. Since cancer cells are sensitive to the effects of bortezomib, this leads to their death or cessation of their growth in the future. Studies have shown that bortezomib causes internal dysfunction in a large number of tumor cell types and causes tumor growth retardation, including multiple myeloma.

The development and production of medicines aimed at the therapy of the main critical diseases, including oncohematological diseases, is one of the most important strategic areas in the work of Promomed Group of Companies, focused on solving significant medical problems, saving and significantly improving the quality of life of patients.

Bortezomib-Promomed, which is included in the VED list, will be produced in the form of a lyophilizate for solution for intravenous and subcutaneous administration with a dosage of 2.5 to 3.5 mg, which corresponds to the standard regimens of administration.